ReviewEye (London, England)2023
Medical treatment for ocular surface squamous neoplasia.
Review in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- New Paradigm in Ocular Surface Squamous Neoplasia-Insights from a Case Report on the Use of Interferon in Treatment.Oncology research · 2026Article
- Topical 5-fluorouracil 1% versus surgical removal as a primary treatment modality for ocular surface squamous neoplasia: a comparison of recurrences and side effects.BMC ophthalmology · 2025Article
- High-resolution optical coherence tomography for screening ocular surface tumors: Historical markers and future directions.World journal of clinical cases · 2025Article
- Differential diagnostic importance of swept-source optical coherence tomography in ocular surface lesions : Swept-source OCT in ocular surface lesions.BMC ophthalmology · 2025Article
- Review
- Presumed reactivation of herpes simplex virus-associated endothelial keratitis after treatment with topical interferon-α 2b for ocular surface squamous neoplasia.BMC ophthalmology · 2025Article
- Conjunctival keratoacanthoma: a clinical and histopathological case series.Canadian journal of ophthalmology. Journal canadien d'ophtalmologie · 2025Article
- Interferon alpha-2b versus 5-fluorouracil as primary treatment modalities for ocular surface squamous neoplasia: a study of 116 eyes.International ophthalmology · 2025Article
- IFNα2b/5-FU inhibits proliferation and cell cycle of squamous carcinoma cell line Cal27.International journal of ophthalmology · 2025Article
- Topical Chemotherapy for Ocular Surface Squamous Neoplasia: A Review of Adverse Effects and Their Clinical Management.Oncology research · 2025Review
- Establishment of a nomogram model to predict malignant risk in patients with ocular surface squamous neoplasia and ocular surface squamous epithelial tumors.Frontiers in oncology · 2025Article
- Infectious etiologies of conjunctival tumors.Expert review of ophthalmology · 2025Article
- Yttrium-90 (American journal of ophthalmology case reports · 2024Article
- Update in ocular surface squamous neoplasia.Revista da Associacao Medica Brasileira (1992) · 2024Review
- Asymptomatic chronic red eye: A surgical technique case report.International journal of surgery case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Ocular surface squamous neoplasia (OSSN) is the most common non-melanocytic tumour of the ocular surface. Surgical excision with wide margins using the "no-touch" method was originally the most popular treatment for OSSN. However, in the past two decades, the use of topical medications for OSSN treatment has gained a reputation amongst ophthalmologists for being an effective alternative to surgical excision. Furthermore, technological advancements, such as those seen in high-resolution optical coherence tomography (HR-OCT) for the anterior segment, have facilitated the diagnosis and monitoring of OSSN. When selecting a topical agent, interferon alpha-2b (IFNα-2b) and 5-fluorouracil (5-FU) are two of the gentlest medications used for OSSN and are often considered first line therapies due to their high-resolution rates and mild side effect profiles. Mitomycin C (MMC), on the other hand, has a highly toxic profile; therefore, while effective, in our hands it is considered as a second-line treatment for OSSN if the other modalities fail. In addition, newer and less studied agents, such as immune checkpoint inhibitors, retinoic acid, aloe vera, and anti-vascular endothelial growth factor have anti-neoplastic properties and have shown potential for the treatment of OSSN. We enclose an updated literature review of medical treatments for OSSN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.